For in-vitro research only · Not for human use · 18+
Australian owned · Independently HPLC tested
This page covers how a research peptide is identified and characterised, how analytical documentation is kept so a result stays traceable, and how to weigh the published evidence behind any given compound. It is written for in-vitro laboratory work and carries no administration guidance of any kind.
A research peptide is defined by its amino acid sequence, not by its trade name. Identity is established by comparing the observed molecular mass from electrospray mass spectrometry against the theoretical mass calculated from that sequence. Sequence, molecular formula and monoisotopic mass belong on the certificate for the lot in hand.
Chain length, net charge at working pH, hydrophobicity and the presence of disulfide bridges or cyclisation all govern how a peptide behaves on a column and in solution. Those same properties explain why two compounds with similar purity figures can require quite different handling at the bench.
Freeze-drying removes water by sublimation under vacuum, leaving an amorphous cake that is far more stable than a solution. Lyophilised peptide remains hygroscopic, so vials are held sealed and cold, brought to room temperature before opening, and logged against their lot on receipt.
Purity is a property of one synthesis and purification run. A figure quoted for a compound rather than a lot cannot be checked against anything. The lot number printed on the vial is the only key that ties material to a test result.
Each intake is recorded against its lot, analysed, released or rejected, and then linked to the certificate produced for it. Verification is simply reading that chain backwards from the vial in your hand.
Main-peak area percent at 214nm describes the chromatographic profile of what was injected. It is not peptide content by mass, and material that does not absorb at that wavelength does not appear at all.
Logging lot number, test date and method beside experimental data is what lets a result be re-examined later. Without it, an anomaly cannot be separated from a material problem.
PubMed and DOI-resolved journal articles are the appropriate sources for what a compound has been studied for. Supplier websites — ours included — are not scientific authorities and should not be cited as such.
PubMedThe Therapeutic Goods Administration publishes the scheduling and approval status of substances in Australia. Research-grade material is not an approved therapeutic good and is not supplied as one.
Therapeutic Goods AdministrationMost peptide literature is in-vitro or animal work. Effects observed in a cell line or rodent model do not transfer to other systems, and small, unreplicated or industry-funded studies carry correspondingly less weight.
NHMRC research standardsEverything supplied by Aussie Peptides is for in-vitro laboratory research only. It is not for human or veterinary use, is not a medicine, and is not approved by the Therapeutic Goods Administration. We publish handling, storage and analytical information; we do not publish administration guidance, and we will not supply it on request.
